Adicet Bio Inc (NAS:ACET)
$ 1.44 -0.03 (-2.04%) Market Cap: 118.32 Mil Enterprise Value: -18.00 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 54/100

Adicet Bio Inc ADI-001 Interim Clinical Data Call Transcript

Dec 06, 2021 / 01:30PM GMT
Release Date Price: $13.57 (+38.47%)
Operator

Good morning, everyone, and welcome to Adicet Specially scheduled conference call. This call is being recorded.

(Operator Instructions)

I would now like to turn the call over to (inaudible). Please go ahead.

Unidentified Company Representative

Thank you. On the call today from Adicet are Chen Schor, President and CEO; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer.

In addition, we're pleased to have Dr. Sattva Neelapu, professor in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center joining us today. We'll start the presentation with an introductory remarks by Chen, and then Francesco will review the interim results in more detail. Dr. Neelapu will then provide his thoughts on the data and speak to the potential opportunities offered by gamma delta CAR T cell therapy. After that, we'll open up the call for Q&A.

But before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot